Abstract: The present disclosure provides a strengthened glass and a glass strengthening method, and an electronic device housing. Two opposing sides of the strengthened glass have surface compressive stress layers, and a third stress layer is sandwiched between the two surface compressive stress layers. The third stress layer includes a compressive stress region and multiple tensile stress regions spaced apart within the compressive stress region, the multiple tensile stress regions are extended in a thickness direction of the strengthened glass, and each of the tensile stress regions is surrounded by the compressive stress region. A sum of thicknesses of the surface compressive stress layers and a thickness of the compressive stress region located between two adjacent tensile stress regions is equal to a thickness of the strengthened glass.

Abstract: Provided are a method, a device and electronic equipment for detecting a stability of a generator set in a power system. The method includes following steps: determining a target matrix by using Liapunov's direct method based on a state space matrix corresponding to power management unit (PMU) data; obtaining a state deviation corresponding to the PMU data and an oscillation curve corresponding to the state deviation in a case of determining the power system being in a stable state according to the target matrix; determining extreme point values corresponding to the oscillation curve at each oscillation; and evaluating a working state of the generator set in the power system according to the extreme point values.

Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).

Abstract: A page display method is provided. The method includes determining a first page based on a first operation on a client; and obtaining, in response to the first operation on the client, current scenario information of the client and a first target page set that is generated according to a page jump historical record of the first page. The method also includes determining a second target page set corresponding to the current scenario information according to a correspondence between scenario information and target pages in the first target page set; creating a corresponding page-entry control for at least one page in the second target page set; and displaying the first page and the page-entry control for at least one page.

Abstract: A modular microcode (uCode) patch method to support runtime persistent update and associated apparatus. The method enables BIOS uCode patches to be received during platform runtime operations and written to first and second uCode extension regions as uCode images for a firmware device layout that further includes a uCode base region in which a current uCode image is stored. Following a platform reset, the first and second uCode extension regions are inspected to determine if one or more valid and newer uCode images (than the current uCode image) are present. If so, the newest uCode image is booted rather than the current uCode image. Following a successful boot, the newest uCode image is copied to the uCode base region to sync-up the current uCode image to the newest version. In one aspect, received uCode images are written to the first and second uCode extension regions in an alternating manner to support roll-back.

Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).

Abstract: A page display method is provided. The method includes determining a first page based on a first operation on a client; and obtaining, in response to the first operation on the client, current scenario information of the client and a first target page set that is generated according to a page jump historical record of the first page. The method also includes determining a second target page set corresponding to the current scenario information according to a correspondence between scenario information and target pages in the first target page set; creating a corresponding page-entry control for at least one page in the second target page set; and displaying the first page and the page-entry control for at least one page.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

Abstract: A mobile-type maintenance square-shaped bin including a bin body, a travelling mechanism provided under the bin body, a car head connected with one end of the bin body, an inlet and an outlet provided at the other end of the bin body, a sealed door provided on the inlet and the outlet, an allocation and transportation device mutually connected with a microcomputer signal provided at a front end of the bin body as well as provided over an internal portion of the bind body, an maintenance platform provided at a bottom of the internal portion of the bin body, a tool platform provided adjacently to the maintenance platform, an ash-removal mechanism provided at an upper portion of the maintenance platform, an air-conditioning device provided at an outer portion of the bin body, and a scanning mechanism provided at a front portion of the maintenance platform.

Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

Abstract: A mobile-type maintenance square-shaped bin including a bin body, a travelling mechanism provided under the bin body, a car head connected with one end of the bin body, an inlet and an outlet provided at the other end of the bin body, a sealed door provided on the inlet and the outlet, an allocation and transportation device mutually connected with a microcomputer signal provided at a front end of the bin body as well as provided over an internal portion of the bind body, an maintenance platform provided at a bottom of the internal portion of the bin body, a tool platform provided adjacently to the maintenance platform, an ash-removal mechanism provided at an upper portion of the maintenance platform, an air-conditioning device provided at an outer portion of the bin body, and a scanning mechanism provided at a front portion of the maintenance platform.